Attached files

file filename
10-K - 10-K - PLURISTEM THERAPEUTICS INCzk1822069.htm
EX-32.3 - EXHIBIT 32.3 - PLURISTEM THERAPEUTICS INCexhibit_32-3.htm
EX-32.2 - EXHIBIT 32.2 - PLURISTEM THERAPEUTICS INCexhibit_32-2.htm
EX-31.3 - EXHIBIT 31.3 - PLURISTEM THERAPEUTICS INCexhibit_31-3.htm
EX-31.2 - EXHIBIT 31.2 - PLURISTEM THERAPEUTICS INCexhibit_31-2.htm
EX-31.1 - EXHIBIT 31.1 - PLURISTEM THERAPEUTICS INCexhibit_31-1.htm
EX-23.1 - EXHIBIT 23.1 - PLURISTEM THERAPEUTICS INCexhibit_23-1.htm
EX-10.22 - EXHIBIT 10.22 - PLURISTEM THERAPEUTICS INCexhibit_10-22.htm
EX-10.21 - EXHIBIT 10.21 - PLURISTEM THERAPEUTICS INCexhibit_10-21.htm
EX-10.20 - EXHIBIT 10.20 - PLURISTEM THERAPEUTICS INCexhibit_10-20.htm


Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
 
In connection with the Annual Report on Form 10-K of Pluristem Therapeutics Inc. (the "Company") for the period ended June 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, as the Co-Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350,  that, to my knowledge:
 
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
 
Dated: September 12, 2018
 
 
/s/ Zami Aberman
Zami Aberman
Co-Chief Executive Officer